• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine
  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Pharma & Human Health

Finance

Cmbio: A New Brand Unifying Global Leaders in Microbiome and Metabolomics Science

November 19, 2024 Microbiome Times

Today marks the launch of Cmbio, a new brand that brings together Clinical Microbiomics (Europe), CosmosID (North America), MS-Omics (Europe), DNASense (Europe), and Microba’s Research Services Unit (Australia and Asia) under one identity. United under […]

Finance

Freya Biosciences Announces $10.4 Million Strategic Investment from the Bill & Melinda Gates Foundation

November 19, 2024 Microbiome Times

The new investment extends Series A investment to about $50 million Freya Biosciences, a transatlantic biotech company specializing in women’s health, today announces a $10.4 million strategic investment from the Bill & Melinda Gates Foundation […]

Editor's Choice

Lallemand’s New R&D Laboratories: An Exclusive Interview with Sylvie Binda, VP of R&D

November 15, 2024 Microbiome Times

Following the announcement of Lallemand’s new R&D laboratories in France, Microbiome Times caught up with Sylvie Binda, VP of R&D to discuss the company’s goals and objectives. Can you elaborate on how the new laboratories […]

Pharma & Human Health

Quadram Institute announces Professor Daniel Figeys as new Director and Chief Executive

November 12, 2024 Microbiome Times

Professor Figeys is the founding Director of the School of Pharmaceutical Sciences and of the Ottawa Institute of Systems Biology, Faculty of Medicine, at the University of Ottawa in Canada. His research focuses on developing […]

Pharma & Human Health

EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis

November 11, 2024 Microbiome Times

EnteroBiotix Limited (‘EnteroBiotix’ or the ‘Company’), a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced positive results from its Phase 1b IMPuLCE study evaluating EBX-102 in patients with liver cirrhosis. EnteroBiotix’s […]

Pharma & Human Health

Updates from MaaT Pharma’s Early Access Program Demonstrate Prolonged Long-Term Survival in Patients Receiving MaaT013

November 8, 2024 Microbiome Times

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced updated […]

Pharma & Human Health

Researchers hope to develop novel drugs for gastrointestinal disorders by fermenting feces

November 7, 2024 Microbiome Times

In a new study, researchers at the University of Copenhagen have been cultivating ‘good viruses’ from feces. The goal is to replace fecal capsules now being used in so-called fecal transplants. Their new technique has […]

Pharma & Human Health

Cerillo Introduces First Standardized Co-Culture System Revolutionizing Microbial Interaction and Isolation Studies

October 24, 2024 Microbiome Times

Cerillo, a leader in cellular analytics, announces the release of Duet, the first standardized co-culture system that allows researchers to explore microbial and cellular interactions in real time. Designed to address challenges in microbial research, Duet offers a […]

Editor's Choice

Health Canada Licenses Probiotical’s PROBIAL DERM® for Eczema and Atopic Dermatitis Claims

October 22, 2024 Microbiome Times

Eczema and Atopic Dermatitis (AD) is thought to affect as many as 10% of adults worldwide and represents a debilitating condition for many.1 It can result in a lower quality of life, and reports link […]

Editor's Choice

Precision metagenomics: a rapid solution for identifying and characterizing microbial agents of infectious disease.

October 17, 2024 Microbiome Times

Next-generation sequencing (NGS) represents an innovative and versatile technology for microbial identification and characterization. NGS offers flexibility to scale methods based on the experimental interest. Widely available NGS methods include amplicon sequencing, hybrid capture, whole-genome […]

Pharma & Human Health

Sequential Launches Industry-First Microbiome Target Panels for Skin Conditions

October 16, 2024 Microbiome Times

Sequential is excited to announce the launch of the industry’s first-ever Targeted Skin Condition Panels through the lens of the Microbiome, designed to address major skin concerns such as acne, rosacea, atopic dermatitis, malodor, and […]

Posts navigation

« 1 … 6 7 8 … 85 »

Sign Up to Free Newsletter

Editor’s Choice

  • Siolta Therapeutics Reports Positive Phase 2 Results from the ADORED Study
    November 17, 2025
  • The OMNIgene™•VAGINAL device – Optimized solutions for vaginal microbiome studies
    November 12, 2025
  • MRM Health Raises €55 Million Series B to Advance Microbiome-Based Biotherapeutic Product Pipeline
    September 4, 2025
  • Targeting the ileo-colonic region: Innovative solutions for sensitive APIs
    August 21, 2025
  • EXPERT’Biome CDMO by Lallemand at Microbiome Times Forum
    June 23, 2025
sign up

Sign up to the Microbiome Times newsletter